Trial intelligence / Profile preview

PEHAB-II: Penile Rehabilitation After Prostatectomy

NCT06875258Phase 4Recruiting

Sponsor
Netherlands Cancer Institute
Start
Jan 2024
Primary completion
Jan 2027
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, randomised, open-label trial of sildenafil in erectile dysfunction (ED) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Adequate unassisted erection sufficient for successful sexual intercourse without medication or devices at 24 months. Started Jan 2024; status: recruiting.

02

Drugs

sildenafil
03

Conditions

erectile dysfunction (ED)

Beyond the preview

Go deeper on NCT06875258.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06875258.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call